Culture-Expanded Stem Cells: Why Colombia Can Offer What the US Cannot

This is the single most important regulatory distinction in stem cell medicine — and the primary reason Americans travel to Colombia for treatment. In the United States, culture-expanded stem cells are classified as biologic drugs requiring FDA approval (IND/BLA pathway). In Colombia, the same cells are permitted under INVIMA oversight at certified laboratories. This difference is not a loophole — it is a deliberate regulatory framework difference that reflects different national approaches to cell therapy oversight.

Why the FDA Takes This Position

The FDA's concern is legitimate: culture expansion involves growing cells outside the body for days to weeks in a laboratory. During this process, cells can change characteristics, become contaminated, or lose potency. The FDA's position is that this level of manipulation transforms cells from a medical procedure into a manufactured product — and manufactured products need rigorous testing before human use.

Colombia's INVIMA takes a different but equally defensible position: that culture expansion performed at certified laboratories with proper quality controls is a medical procedure that can be regulated through facility oversight rather than individual product approval. Both approaches have merit. The practical result is that Colombian patients have access to treatments that American patients do not.

For treatment consultations at INVIMA-certified facilities, visit colombiastemcelltreatment.com or the broader network at colombiamedical.co.